| 2025-11-03 |
详情>>
股本变动：
变动后总股本1705.09万股
|
| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-10.93美元,归母净利润-9384.1万美元,同比去年增长-105.6%
|
| 2025-11-03 |
财报披露：
美东时间 2025-11-03 盘前发布财报
|
| 2025-10-15 |
详情>>
内部人交易：
Macomber Lori等共交易6笔
|
| 2025-08-16 |
复牌提示：
2025-08-15 12:32:59 停牌，复牌日期 2025-08-15 12:37:59
|
| 2025-08-11 |
详情>>
业绩披露：
2025年中报每股收益-7.11美元,归母净利润-6071.4万美元,同比去年增长-347.41%
|
| 2025-05-12 |
详情>>
业绩披露：
2025年一季报每股收益-2.77美元,归母净利润-2346.2万美元,同比去年增长37.20%
|
| 2025-04-14 |
股东大会：
将于2025-05-28召开股东大会
会议内容 ▼▲
- 1.To elect the following two Class III directors nominated by our Board of Directors to serve as directors, each to hold office for a three-year term to expire at the 2028 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified: Garen G. Bohlin and Zhen Su, M.D., M.B.A.;
2.To approve an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of our common stock available for issuance thereunder by 450,000 shares;
3.To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;
4.To recommend, on an advisory basis, the frequency of future non-binding advisory votes on the compensation of our named executive officers;
5.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2025;
6.To consider and vote upon such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-02-24 |
详情>>
拆分方案：
每15.0000合并分成1.0000股
|
| 2025-02-19 |
详情>>
业绩披露：
2022年年报每股收益-2.02美元,归母净利润-1.65亿美元,同比去年增长-33.2%
|
| 2025-02-19 |
详情>>
业绩披露：
2024年年报每股收益-0.63美元,归母净利润-7642.2万美元,同比去年增长46.60%
|
| 2024-12-16 |
股东大会：
将于2025-01-30召开股东大会
会议内容 ▼▲
- 1.To adopt and approve an amendment to our Restated Certificate of Incorporation (as amended, the “Restated Certificate of Incorporation”) to increase the number of authorized shares of our capital stock from 405,000,000 to 805,000,000 and the number of authorized shares of our common stock from 400,000,000 to 800,000,000 (the “Authorized Shares Proposal”);
2.To adopt and approve an amendment to our Restated Certificate of Incorporation to effect a reverse stock split of our issued shares of common stock at a ratio within the range of not less than 1-for-5 and not greater than 1-for-15, and a proportionate reduction in the number of authorized shares of common stock, with the exact ratio within such range and the implementation and timing of such reverse stock split to be determined at the sole discretion of our Board of Directors, without further approval or authorization of our stockholders (the “Reverse Split Proposal”);
3.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary to permit further solicitation of proxies in the event that there are insufficient votes for the adoption and approval of the Authorized Shares Proposal or the Reverse Split Proposal.
|
| 2024-11-05 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-0.38美元,归母净利润-4564.2万美元,同比去年增长54.93%
|
| 2024-08-06 |
详情>>
业绩披露：
2024年中报每股收益-0.11美元,归母净利润-1357万美元,同比去年增长79.67%
|
| 2024-08-06 |
详情>>
业绩披露：
2023年中报每股收益-0.59美元,归母净利润-6675.6万美元,同比去年增长26.20%
|
| 2024-05-08 |
详情>>
业绩披露：
2024年一季报每股收益-0.32美元,归母净利润-3736.2万美元,同比去年增长-9.48%
|
| 2024-04-19 |
股东大会：
将于2024-05-29召开股东大会
会议内容 ▼▲
- 1.To elect the following three Class II directors nominated by our Board of Directors to serve as directors, each to hold office for a three-year term to expire at the 2027 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified: Deepika R. Pakianathan, Ph.D., Richard Paulson, M.B.A. and Chen Schor, M.B.A., C.P.A.;
2.To approve an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan, as amended, to increase the number of shares of our common stock available for issuance thereunder by 6,000,000 shares;
3.To approve an amendment to the Karyopharm Therapeutics Inc. Amended & Restated 2013 Employee Stock Purchase Plan to increase the number of shares of our common stock available for issuance thereunder by 5,000,000 shares;
4.To approve a one-time stock option exchange program for non-executive officer employees;
5.To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;
6.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2024;
7.To consider and vote upon such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-02-29 |
详情>>
业绩披露：
2023年年报每股收益-1.25美元,归母净利润-1.43亿美元,同比去年增长13.43%
|
| 2023-11-02 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.89美元,归母净利润-1.01亿美元,同比去年增长20.13%
|
| 2023-04-11 |
股东大会：
将于2023-05-24召开股东大会
会议内容 ▼▲
- 1.To elect the following three Class I directors nominated by our Board of Directors to serve as directors, each to hold office for a three-year term to expire at the 2026 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified: Barry E. Greene, Mansoor Raza Mirza, M.D. and Christy J. Oliger;
2.To approve an amendment to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan to increase the number of shares of our common stock available for issuance thereunder by 5,000,000 shares;
3.To approve the amendment and restatement of the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan;
4.To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 200,000,000 to 400,000,000;
5.To approve an amendment to our Restated Certificate of Incorporation, as amended, to reflect new Delaware law provisions regarding officer exculpation;
6.To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;
7.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2023;
8.To consider and vote upon such other business as may be properly brought before the Annual Meeting or any adjournments or postponements thereof.
|
| 2022-04-08 |
股东大会：
将于2022-05-19召开股东大会
会议内容 ▼▲
- 1.To elect the following two Class III directors nominated by our Board of Directors to serve as directors, each to hold office for a three-year term to expire at the 2025 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified: Garen G. Bohlin and Peter Honig, M.D., M.P.H.;
2.To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;
3.To approve the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan;
4.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2022;
5.To consider and vote upon such other business as may be properly brought before the meeting or any adjournments or postponements thereof.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-07 |
股东大会：
将于2021-05-21召开股东大会
会议内容 ▼▲
- 1.To elect the following three Class II directors nominated by our Board of Directors to serve as directors, each to hold office for a three-year term to expire at the 2024 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified: Deepika R. Pakianathan, Ph.D., Richard Paulson, M.B.A., and Chen Schor, M.B.A., C.P.A.;
2.To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2021;
4.To consider and vote upon such other business as may be properly brought before the meeting or any adjournments or postponements thereof.
|
| 2020-04-09 |
股东大会：
将于2020-05-21召开股东大会
会议内容 ▼▲
- 1.To elect the following two Class I directors nominated by our Board of Directors to serve as directors, each to hold office for a three-year term to expire at the 2023 annual meeting of stockholders and until their resignation or removal or until their successors are duly elected and qualified: Barry E. Greene and Mansoor Raza Mirza, M.D.;
2.To approve, on an advisory basis, the compensation of our named executive officers, as described in this proxy statement;
3.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the year ending December 31, 2020;
4.To consider and vote upon such other business as may be properly brought before the meeting or any adjournments or postponements thereof.
|
| 2019-04-19 |
股东大会：
将于2019-06-06召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors to serve for a three-year term to expire at the 2022 annual meeting of stockholders;
2.To approve, on a non-binding advisory basis, the compensation of our named executive officers, as described in the “Compensation Discussion and Analysis,” executive compensation tables and accompanying narrative disclosures in this proxy statement;
3.To recommend, on a non-binding advisory basis, the frequency of future advisory votes on the compensation of our named executive officers;
4.To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2019;
5.To approve an amendment to our Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 to 200,000,000;
6.To consider and vote upon such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2018-04-27 |
股东大会：
将于2018-06-19召开股东大会
会议内容 ▼▲
- 1.To elect one Class II director to serve for a three-year term to expire at the 2021 annual meeting of stockholders;
2.To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2018;
3.To consider and vote upon such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2017-04-28 |
股东大会：
将于2017-06-15召开股东大会
会议内容 ▼▲
- 1. To elect three Class I directors, each to serve for a three-year term to expire at the 2020 annual meeting of stockholders;
2. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2017;
3. To consider and vote upon such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|
| 2016-04-29 |
股东大会：
将于2016-06-16召开股东大会
会议内容 ▼▲
- 1. To elect three directors to serve as Class III directors for a three-year term to expire at the 2019 annual meeting of stockholders;
2. To consider and vote upon the ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2016;
3. To transact such other business as may be properly brought before the meeting or any adjournment or postponement thereof.
|